WuXi Advanced Therapies, a business unit of WuXi AppTec, has announced the completion of a facility expansion that will triple its advanced testing capacity at the company's Philadelphia Navy Yard campus. The expanded laboratory will provide testing services for cell and gene therapy and biotherapy clients globally.
WuXi ATU's new 140,000 sq. ft. state of the art laboratory will increase analytical development and testing capacity and capability and enabling advanced therapy companies to obtain timely characterization and lot release services.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
"WuXi Advanced Therapies is well aware of the impact caused by product-testing bottlenecks for the advanced therapies industry. As a leading cell and gene therapy Contract Testing Development and Manufacturing Organization (CTDMO), we are addressing the challenge with this important new investment at the Philadelphia Navy Yard – which reflects our sustained commitment to our customers by getting advanced therapeutic solutions to patients sooner," said Dr. David Chang, Chief Executive Officer of WuXi ATU.
The new facility, WuXi ATU's fourth at the Philadelphia Navy Yard, is Gold LEED-certified and adheres to Good Manufacturing Practices. The laboratory is scheduled to begin operations in late 2020.